Strong Cresemba sales in the USA trigger first sales milestone payment to Basilea

25 October 2017

Swiss drugmaker Basilea Pharmaceutica (SIX: BSLN) says that the sales of the antifungal Cresemba (isavuconazole) in the USA exceeded the threshold triggering the first sales milestone payment from licensee Astellas Pharma (TYO: 4503) to Basilea in the amount of 5 million Swiss francs ($5.1 million).

David Veitch, chief commercial officer of Basilea, said: "We are very pleased with the continued commercial success of Cresemba in the US reflecting the medical need for agents treating invasive aspergillosis and invasive mucormycosis in adults and the increasing importance of Cresemba in the treatment of adults suffering from these potentially life-threatening invasive fungal infections that predominantly affect immunocompromized patients, such as patients with cancer and after transplantation."

Under the agreement with Astellas, Basilea is still eligible for additional sales milestone payments of up to 285 million francs in addition to tiered, double-digit royalties on US sales. The drug was approved in the USA in March 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK